Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor–Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis

IMPORTANCE: One of the most recent treatment regimens used for hormone receptor (HR)–positive, ERBB2 (formerly HER2)–negative metastatic breast cancer is treatment with the cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and endocrine therapy (ET). OBJECTIVE: To assess overall survival (OS), pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jinming, Huo, Xingfa, Zhao, Fuxing, Ren, Dengfeng, Ahmad, Raees, Yuan, Xinyue, Du, Feng, Zhao, Jiuda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094425/
https://www.ncbi.nlm.nih.gov/pubmed/33048129
http://dx.doi.org/10.1001/jamanetworkopen.2020.20312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094425/
https://www.ncbi.nlm.nih.gov/pubmed/33048129
http://dx.doi.org/10.1001/jamanetworkopen.2020.20312

Ejemplares similares